These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 8167888)

  • 1. Effect of nafamostat mesilate on coagulation and fibrinolysis in hepatic resection.
    Shimada M; Matsumata T; Shirabe K; Kamakura T; Taketomi A; Sugimachi K
    J Am Coll Surg; 1994 May; 178(5):498-502. PubMed ID: 8167888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nafamostat mesilate, a synthetic protease inhibitor, on immunity and coagulation after hepatic resection.
    Inagaki H; Nonami T; Kurokawa T; Takeuchi Y; Okuda N; Nakao A; Sakamoto J
    Hepatogastroenterology; 1999; 46(30):3223-8. PubMed ID: 10626190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative hypercoagulable state followed by hyperfibrinolysis related to wound healing after hepatic resection.
    Tsuji K; Eguchi Y; Kodama M
    J Am Coll Surg; 1996 Sep; 183(3):230-8. PubMed ID: 8784316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
    Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
    Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprotinin and nafamostat mesilate in liver surgery: effect on blood loss.
    Pereboom IT; de Boer MT; Porte RJ; Molenaar IQ
    Dig Surg; 2007; 24(4):282-7. PubMed ID: 17657153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials.
    Usui A; Hiroura M; Kawamura M; Hibi M; Yoshida K; Murakami F; Tomita Y; Ooshima H; Murase M
    Ann Thorac Surg; 1996 Nov; 62(5):1404-11. PubMed ID: 8893576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experimental and clinical studies on blood coagulation and lysis system after hepatic resection (author's transl)].
    Saito I
    Hokkaido Igaku Zasshi; 1979 Jul; 54(4):401-15. PubMed ID: 231002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
    Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
    ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of a protease inhibitor against hepatectomy.
    Gotohda N; Iwagaki H; Ozaki M; Konishi M; Nakagohri T; Takahashi S; Yagi T; Kinoshita T; Tanaka N
    Hepatogastroenterology; 2006; 53(67):115-9. PubMed ID: 16506388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Responses to surgical stress in blood coagulation and fibrinolysis, platelet counts and thromboxane B2 after esophageal cancer operation].
    Shinohara M; Kurokawa H; Yoshihara Y; Kokubu S; Kusano T; Horie K; Murakami N; Nagai K; Nara N
    Rinsho Byori; 1997 Feb; 45(2):179-84. PubMed ID: 9121003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with major intraoperative blood loss in hepatic resection for hepatobiliary tumor.
    Sirichindakul B; Chanwat R; Nonthasoot B; Suphapol J; Nivatvongs S
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S54-8. PubMed ID: 16623003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of bloodless hepatectomy under occlusion of total hemi-hepatic vessel].
    Yang JM; Tong Y; Xie F; Xu F; Kan T; Shen WF; Wu MC
    Zhonghua Wai Ke Za Zhi; 2007 Feb; 45(3):186-8. PubMed ID: 17498379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental Extracorporeal Life Support (ECLS).
    Mellgren K; Skogby M; Friberg LG; Tengborn L; Wadenvik H
    Thromb Haemost; 1998 Feb; 79(2):342-7. PubMed ID: 9493588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of coagulation and fibrinolysis in hepatic resection: a randomized prospective control study using antithrombin III concentrates.
    Shimada M; Matsumata T; Kamakura T; Hayashi H; Urata K; Sugimachi K
    Thromb Res; 1994 Apr; 74(2):105-14. PubMed ID: 8029811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The protease inhibitor gabexate mesilate in experimentally-induced acute pancreatitis with early gram-negative infection in the Göttingen minipig: therapeutic efficacy and effects on blood coagulation and fibrinolysis].
    Heitz J; Semsch B; Emde C; Jansen U; Schäfer JH
    Z Gastroenterol; 1990 Apr; 28(4):192-7. PubMed ID: 2119091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.
    Llamas P; Cabrera R; Gómez-Arnau J; Fernández MN
    Haematologica; 1998 Apr; 83(4):338-46. PubMed ID: 9592984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.
    Hryszko T; Inaba K; Ihara H; Suzuki Y; Mogami H; Urano T
    J Trauma; 2006 Apr; 60(4):859-64. PubMed ID: 16612309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis system in patients with bronchial asthma.
    Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
    Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.